BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1055 related articles for article (PubMed ID: 27286975)

  • 21. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
    Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
    Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells.
    Librizzi M; Spencer J; Luparello C
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
    Ono H; Sowa Y; Horinaka M; Iizumi Y; Watanabe M; Morita M; Nishimoto E; Taguchi T; Sakai T
    Breast Cancer Res Treat; 2018 Aug; 171(1):43-52. PubMed ID: 29752686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.
    Wang ZT; Chen ZJ; Jiang GM; Wu YM; Liu T; Yi YM; Zeng J; Du J; Wang HS
    Cell Signal; 2016 May; 28(5):506-515. PubMed ID: 26876786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.
    Zhao YQ; Yin YQ; Liu J; Wang GH; Huang J; Zhu LJ; Wang JH
    Acta Pharmacol Sin; 2016 Sep; 37(9):1237-50. PubMed ID: 27397540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in Vivo.
    Li HC; Xia ZH; Chen YF; Yang F; Feng W; Cai H; Mei Y; Jiang YM; Xu K; Feng DX
    Cell Physiol Biochem; 2017; 43(5):1829-1840. PubMed ID: 29050003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the proapoptotic regulator Bcl2/adenovirus EIB 19 kDa-interacting protein 3 on radiosensitivity of cervical cancer.
    Wang Z; Huang CM; Deng Q; Zeng H; Wang X; Zhang S; Bi F; Tang QL; Zhong RM; Li AJ; He YB; Chen N; Li ZP; Wang W
    Cancer Biother Radiopharm; 2011 Jun; 26(3):279-86. PubMed ID: 21711117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo.
    Hsieh YL; Tu HJ; Pan SL; Liou JP; Yang CR
    Biochim Biophys Acta Mol Cell Res; 2019 Jun; 1866(6):992-1003. PubMed ID: 30867138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Downregulation of TMPRSS4 Enhances Triple-Negative Breast Cancer Cell Radiosensitivity Through Cell Cycle and Cell Apoptosis Process Impairment.
    Assani G; Segbo J; Yu X; Yessoufou A; Xiong Y; Zhou F; Zhou Y
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3679-3687. PubMed ID: 31870109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
    Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
    Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies.
    Huang WJ; Tang YA; Chen MY; Wang YJ; Hu FH; Wang TW; Chao SW; Chiu HW; Yeh YL; Chang HY; Juan HF; Lin P; Wang YC
    Cancer Lett; 2014 Apr; 346(1):84-93. PubMed ID: 24355296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triptolide Decreases Cell Proliferation and Induces Cell Death in Triple Negative MDA-MB-231 Breast Cancer Cells.
    Varghese E; Samuel SM; Varghese S; Cheema S; Mamtani R; Büsselberg D
    Biomolecules; 2018 Dec; 8(4):. PubMed ID: 30563138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells.
    Komatsu S; Moriya S; Che XF; Yokoyama T; Kohno N; Miyazawa K
    Biochem Biophys Res Commun; 2013 Jul; 437(1):41-7. PubMed ID: 23792097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.
    Hanke NT; Garland LL; Baker AF
    J Cancer Res Clin Oncol; 2016 Mar; 142(3):549-60. PubMed ID: 26385374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.
    Stauber RH; Knauer SK; Habtemichael N; Bier C; Unruhe B; Weisheit S; Spange S; Nonnenmacher F; Fetz V; Ginter T; Reichardt S; Liebmann C; Schneider G; Krämer OH
    Oncotarget; 2012 Jan; 3(1):31-43. PubMed ID: 22289787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.
    Seo SK; Jin HO; Woo SH; Kim YS; An S; Lee JH; Hong SI; Lee KH; Choe TB; Park IC
    J Thorac Oncol; 2011 Aug; 6(8):1313-9. PubMed ID: 21642861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.